scholarly journals Probiotic pretreatment improves survival and prevents gut mucosal barrier dysfunction in sepsis

Critical Care ◽  
2014 ◽  
Vol 18 (S2) ◽  
Author(s):  
KL Calisto ◽  
ACAP Camacho ◽  
FC Mittestainer ◽  
MCS Mendes ◽  
AC Santos ◽  
...  
2020 ◽  
Vol 2020 ◽  
pp. 1-8 ◽  
Author(s):  
Xia Liu ◽  
Yiwen Cheng ◽  
Li Shao ◽  
Zongxin Ling

Growing evidence indicated that the gut microbiota was the intrinsic and essential component of the cancer microenvironment, which played vital roles in the development and progression of colorectal cancer (CRC). In our present study, we investigated the alterations of fecal abundant microbiota with real-time quantitative PCR and the changes of indicators of gut mucosal barrier from 53 early-stage CRC patients and 45 matched healthy controls. We found that the traditional beneficial bacteria such as Lactobacillus and Bifidobacterium decreased significantly and the carcinogenic bacteria such as Enterobacteriaceae and Fusobacterium nucleatum were significantly increased in CRC patients. We also found gut mucosal barrier dysfunction in CRC patients with increased levels of endotoxin (LPS), D-lactate, and diamine oxidase (DAO). With Pearson’s correlation analysis, D-lactate, LPS, and DAO were correlated negatively with Lactobacillus and Bifidobacterium and positively with Enterobacteriaceae and F. nucleatum. Our present study found dysbiosis of the fecal microbiota and dysfunction of the gut mucosal barrier in patients with early-stage CRC, which implicated that fecal abundant bacteria and gut mucosal barrier indicators could be used as targets to monitor the development and progression of CRC in a noninvasive and dynamic manner.


2005 ◽  
Vol 33 ◽  
pp. A32
Author(s):  
Carlos A Macias ◽  
Jeffrey W Chiao ◽  
Yulia Y Tyurina ◽  
Peter Wipf ◽  
Jingbo Xiao ◽  
...  

Author(s):  
Ming Xin Li ◽  
Jun Feng Liu ◽  
Jian Da Lu ◽  
Ying Zhu ◽  
Ding Wei Kuang ◽  
...  

2021 ◽  
Author(s):  
Xuemeng Si ◽  
Ning Liu ◽  
Hai Jia ◽  
Jiaqi Wang ◽  
Lina Pan ◽  
...  

Gut relief formula administration alleviated mucosal inflammation and mucosal barrier dysfunction by inhibiting STAT3 and NF-κB activity and upregulating abundances of Lactobacillus in DSS-induced colitis.


Sign in / Sign up

Export Citation Format

Share Document